go-v.orgdoi

Analysis of Methylation‐driven Genes in Pancreatic Ductal Adenocarcinoma for Predicting Prognosis

Zihan Zhang, Rui Zhu, Wentian Sun, Jun Wang, Jin Liu · Journal of Cancer · 2021

  • DOI 10.7150/jca.53208
  • Publisher Ivyspring International Publisher
  • Type article
  • Issued 2021

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Journal of Cancer · Ivyspring International Publisher · article · 2021

Abstract

Purpose: Considerable variations in methylation profile have been found in various cancers to modulate tumorigenesis and affect prognosis.To provide a theoretical basis for early detection, prognosis evaluation and targeted treatment for patients with pancreatic ductal adenocarcinoma: PDAC, this study identified methylation-driven genes in PDAC and explored their prognostic performance.Methods: The methylation, expression and clinical data of PDAC patients were extracted from TCGA database.Based on the β-mixture model of the MethylMix R package, the differential methylation status and connection between methylation and expression degree were examined to screen out methylationdriven genes in PDAC.COX analyses and lasso regressions were applied to construct a linear risk model based on methylation-driven genes.Univariate and multivariate analyses were performed to ensure the risk model was an independent prognostic factor.Joint survival analyses of methylation and gene expression were conducted to explore the prognostic value of component genes.The methylation sites in the key genes were also investigated.Results: A total of 118 methylation-driven genes in PDAC were identified, and two genes (FOXI2, MYEOV) constituted the risk model whose AUC was 0.722 at one year of overall survival rate, displaying a better performance on survival prediction than other clinical features.Further survival analyses demonstrated that the expression of MYEOV and combined methylation and expression levels of the genes MYEOV and FOXI2 can be potential biomarkers for survival prediction and targets of drug manipulation of PDAC patients.Close relationships were discovered between two sites in MYEOV and one site in FOXI2 and the prognosis of PDAC patients.Conclusion: Concentrating on DNA methylation, our study identified potential biomarkers and developed a reliable short-term predictive model for prognosis of PDAC patients.

Open the resolved locator · 10.7150/jca.53208

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-19 21:10 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://www.jcancer.org/v12p6507.htm
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.